Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors.
PD-(L)1 inhibitor
immune checkpoint inhibitor
immunotherapy
non-small-cell lung cancer
nutritional status
systemic inflammation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Feb 2023
10 Feb 2023
Historique:
received:
22
12
2022
revised:
30
01
2023
accepted:
08
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patients treated with ICIs in combination with chemotherapy (CT) (ICI + CT) or with CT alone, making it impossible to discriminate a predictive from a prognostic effect. We conducted a single-center retrospective study to search for associations between various baseline biomarkers/scores that reflected the systemic inflammation/nutritional status (Lung Immune Prognostic Index, Modified Lung Immune Prognostic Index, Scottish Inflammatory Prognostic Score, Advanced Lung Cancer Inflammation Index, EPSILoN, Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Gustave Roussy Immune Score, Royal Marsden Hospital Prognostic Score, Lung Immuno-oncology Prognostic Score 3, Lung Immuno-oncology Prognostic Score 4, score published by Holtzman et al., and Glasgow Prognostic Score) and outcomes in metastatic NSCLC treated in a first-line setting either with ICI in monotherapy (cohort 1;
Identifiants
pubmed: 36835030
pii: ijms24043618
doi: 10.3390/ijms24043618
pmc: PMC9966997
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Biol Markers. 2018 Nov;33(4):372-378
pubmed: 30282502
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Front Oncol. 2020 Oct 09;10:572853
pubmed: 33163403
Sci Rep. 2015 Jul 24;5:12493
pubmed: 26205001
J Cancer. 2018 Sep 7;9(18):3295-3302
pubmed: 30271489
J Thorac Oncol. 2021 Apr;16(4):653-664
pubmed: 33333328
BMC Cancer. 2013 Mar 27;13:158
pubmed: 23530866
Ann Transl Med. 2019 Sep;7(18):433
pubmed: 31700869
J Cancer. 2021 Mar 15;12(10):2960-2967
pubmed: 33854596
Lancet Oncol. 2019 Oct;20(10):1395-1408
pubmed: 31422028
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
J Thorac Oncol. 2019 Aug;14(8):1440-1446
pubmed: 30999110
Nutr Cancer. 2017 Nov-Dec;69(8):1151-1176
pubmed: 29083236
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
JAMA Oncol. 2018 Mar 01;4(3):351-357
pubmed: 29327044
Anticancer Res. 2019 Mar;39(3):1455-1461
pubmed: 30842182
ESMO Open. 2022 Apr;7(2):100445
pubmed: 35398717
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Sci Rep. 2016 Jan 29;6:20090
pubmed: 26822379
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Diagnostics (Basel). 2022 Feb 06;12(2):
pubmed: 35204513
Clin Cancer Res. 2020 May 15;26(10):2354-2361
pubmed: 32102950
J Thorac Dis. 2018 Sep;10(9):5298-5307
pubmed: 30416777
Lung Cancer. 2019 Oct;136:45-51
pubmed: 31437663
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Oncol Res Treat. 2021;44(4):164-175
pubmed: 33657566
J Clin Med. 2021 Mar 02;10(5):
pubmed: 33801320
JAMA Oncol. 2019 Oct 01;5(10):1481-1485
pubmed: 31343662
J Thorac Oncol. 2021 Jul;16(7):1086-1098
pubmed: 33845212
Ann Oncol. 2019 Oct 1;30(10):1653-1659
pubmed: 31435660
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Proc Nutr Soc. 2008 Aug;67(3):257-62
pubmed: 18452641
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817541
ESMO Open. 2020 Apr;5(2):
pubmed: 32312757
World J Oncol. 2019 Apr;10(2):90-100
pubmed: 31068989
J Thorac Dis. 2020 Apr;12(4):1520-1528
pubmed: 32395289
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Lung Cancer. 2022 Mar;23(2):122-134
pubmed: 35034862
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
World J Surg Oncol. 2019 Nov 2;17(1):177
pubmed: 31677642
Br J Cancer. 2008 Mar 25;98(6):1029-33
pubmed: 18349817
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1001-5
pubmed: 6438478
ESMO Open. 2021 Apr;6(2):100078
pubmed: 33735802
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Thorac Oncol. 2020 Aug;15(8):1351-1360
pubmed: 32302702
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
ESMO Open. 2021 Oct;6(5):100254
pubmed: 34481329
Acta Oncol. 2022 Jun;61(6):773-776
pubmed: 35574825
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
J Clin Lab Anal. 2019 Oct;33(8):e22964
pubmed: 31282096
Clin Lung Cancer. 2020 Jul;21(4):365-377.e5
pubmed: 32245624
JAMA Oncol. 2022 Aug 1;8(8):1160-1168
pubmed: 35708671
J Thorac Oncol. 2021 Oct;16(10):1718-1732
pubmed: 34048946